This finding is consistent with previous reports suggesting pretreatment albumin can be a potential biomarker predicting a favorable clinical outcome following PD-1 blockade immunotherapy in advanced solid cancers, including gastric cancer, hepatocellular carcinoma, lung cancer, ovarian cancer and urothelial cancer [8,10]. This evidence concerns the gene PDCD1 and ovarian cancer.